• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    10/1/25 8:03:50 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCRX alert in real time by email
    false000088279600008827962025-10-012025-10-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    FORM 8-K
     

     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): October 1, 2025
     


    BioCryst Pharmaceuticals, Inc.
    (Exact name of Registrant as Specified in Its Charter)
     

    Delaware
    000-23186
    62-1413174
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

    4505 Emperor Blvd., Suite 200
    Durham, North Carolina
    (Address of Principal Executive Offices)
     
    27703
    (Zip Code)

    (919) 859-1302
    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered
    Common Stock

    BCRX

    Nasdaq Global Select Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company          ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Introductory Note
     
    As previously announced, on June 27, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst” or the “Company”), and BioCryst Ireland Limited (“BioCryst Ireland”), a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Company, entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Neopharmed Gentili S.p.A., a corporation organized under the laws of Italy (the “Purchaser”), pursuant to which, the Company agreed to sell to the Purchaser all of its equity interests in BioCryst Ireland, which together with its subsidiaries holds certain assets and rights related to the Company’s European ORLADEYO® business (the “Transaction”). On October 1, 2025, the Company completed the sale of all of its equity interests in BioCryst Ireland to the Purchaser and received cash proceeds of $250,000,000, subject to customary purchase price adjustments as set forth in the Purchase Agreement.  The description of the Purchase Agreement (and related transactions) does not purport to be complete and is subject to, and qualified by reference to, the full text of the Purchase Agreement filed by the Company as Exhibit 2.1 to its Current Report on Form 8-K dated June 30, 2025.
     
    Item 1.01.
    Entry into a Material Definitive Agreement
     
    In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland amended and restated that certain IP Licence Agreement by and between the Company and BioCryst Ireland, dated as of May 13, 2021 (such amended and restated agreement, the “Amended and Restated IP Licence Agreement”).  Pursuant to the Amended and Restated IP Licence Agreement, the Company granted to BioCryst Ireland an exclusive license under certain patents, solely to the extent reasonably necessary or useful for the commercialization of ORLADEYO® products for use in the Field (as defined in the Amended and Restated IP Licence Agreement) in the Territory (as defined in the Purchase Agreement), and a non-exclusive license under certain know-how, copyrights and other intellectual property, solely to the extent reasonably necessary or useful for the development, manufacture and commercialization of ORLADEYO® products for use in the Field in the Territory, in each case subject to the terms and conditions set forth therein.  The foregoing description of the Amended and Restated IP Licence Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Amended and Restated IP Licence Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated into this Item 1.01 by reference.

    In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland entered into a supply agreement, pursuant to which the Company will be the exclusive supplier of ORLADEYO® products to BioCryst Ireland for commercialization for use in the Field in the Territory (the “Supply Agreement”). The foregoing description of the Supply Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Supply Agreement, a copy of which is filed as Exhibit 10.2 hereto and is incorporated into this Item 1.01 by reference.
     
    In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland entered into a global brand and support agreement, which provides for coordination of brand and regulatory activities between the parties regarding the ORLADEYO® products (the “Global Brand and Support Agreement”). The foregoing description of the Global Brand and Support Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Global Brand and Support Agreement, a copy of which is filed as Exhibit 10.3 hereto and is incorporated into this Item 1.01 by reference.
     
    In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland entered into a mutual transition services agreement pursuant to which BioCryst Ireland and the Company will provide each other with certain transition services for the periods of time and for the compensation as set forth therein (the “Transition Services Agreement”).  Such services will be provided on customary commercial terms.  The foregoing description of the Transition Services Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the text of the Transition Services Agreement, a copy of which is filed as Exhibit 10.4 hereto and is incorporated into this Item 1.01 by reference.

    2

    In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland entered into a trademark license agreement, pursuant to which the Company granted to BioCryst Ireland a non-exclusive transitionary license to use the “BioCryst” name, solely to develop, manufacture and commercialize ORLADEYO® products for use in the Field in the Territory for a limited period of time and an exclusive license to use the ORLADEYO® product name to commercialize ORLADEYO® products for use in the Field in the Territory for the term of the Amended and Restated IP Licence Agreement, in each case subject to the terms and conditions set forth therein (the “Trademark License Agreement”).  The foregoing description of the Trademark License Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Trademark License Agreement, a copy of which is filed as Exhibit 10.5 hereto and is incorporated into this Item 1.01 by reference.

    Item 8.01.
    Other Events

    On October 1, 2025, the Company issued a press release announcing, among other things, the consummation of the Transaction.  A copy of the press release is attached as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

    Item 9.01.
    Financial Statements and Exhibits.

    (d)
    Exhibits

    Exhibit No.

    Description



    10.1

    Amended and Restated IP Licence Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.*



    10.2

    Supply Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.*



    10.3

    Global Brand and Support Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.*



    10.4

    Transition Services Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.*



    10.5

    Trademark License Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.*



    99.1

    Press Release, dated October 1, 2025, regarding the consummation of the Transaction.



    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    *The schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request.

    3

    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     

    BioCryst Pharmaceuticals, Inc.



    Dated: October 1, 2025
    By:
    /s/ Alane Barnes          


    Alane Barnes


    Chief Legal Officer


    4

    Get the next $BCRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCRX

    DatePrice TargetRatingAnalyst
    10/15/2025$30.00Buy
    TD Cowen
    10/1/2025$8.00Outperform → In-line
    Evercore ISI
    4/29/2025$20.00Overweight
    Cantor Fitzgerald
    2/25/2025$15.00Outperform
    Wedbush
    11/20/2023$10.00Overweight
    JP Morgan
    9/18/2023$9.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    8/4/2023$11.00Hold → Buy
    Jefferies
    7/13/2023$10.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $BCRX
    SEC Filings

    View All

    BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    10/14/25 7:10:18 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    10/1/25 8:03:50 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by BioCryst Pharmaceuticals Inc.

    S-8 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    8/12/25 4:09:15 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

    RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years as well as findings on the psychosocial impact of HAE on young patients and their caregivers. BioCryst poster p

    10/23/25 7:00:14 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Report Third Quarter 2025 Financial Results on November 3

    RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob

    10/20/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    TD Cowen resumed coverage on BioCryst Pharma with a new price target

    TD Cowen resumed coverage of BioCryst Pharma with a rating of Buy and set a new price target of $30.00

    10/15/25 8:23:22 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Pharma downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $8.00

    10/1/25 8:12:55 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

    Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00

    4/29/25 8:10:45 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/31/24 4:25:31 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/29/24 4:16:35 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/22/24 7:24:51 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mckee Amy E was granted 676 shares, increasing direct ownership by 2% to 41,007 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    9/3/25 4:30:01 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frank Steven was granted 1,353 shares, increasing direct ownership by 9% to 16,052 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    9/3/25 4:07:34 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Milano Vincent was granted 676 shares, increasing direct ownership by 0.75% to 90,436 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    9/3/25 4:04:50 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Leadership Updates

    Live Leadership Updates

    View All

    BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

    RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. "For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams

    7/9/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

    RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. "Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and

    7/7/25 7:00:22 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Appoints Steve Frank to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct

    5/1/25 7:00:20 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/7/24 10:52:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/7/24 10:25:46 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/4/24 11:18:36 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Financials

    Live finance-specific insights

    View All

    BioCryst to Report Third Quarter 2025 Financial Results on November 3

    RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob

    10/20/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that the companies have entered into a definitive agreement under which BioC

    10/14/25 7:00:00 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)